Get the Stockscreener App
0.236
1.63%
-0.0039
After Hours:
.23
-0.006
-2.54%
Mangoceuticals Inc stock is traded at $0.236, with a volume of 270.09K.
It is down -1.63% in the last 24 hours and down -1.63% over the past month.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
See More
Previous Close:
$0.2399
Open:
$0.249
24h Volume:
270.09K
Relative Volume:
0.34
Market Cap:
$7.06M
Revenue:
-
Net Income/Loss:
$-7.32M
P/E Ratio:
-0.5392
EPS:
-0.4377
Net Cash Flow:
$-5.99M
1W Performance:
-2.07%
1M Performance:
-1.63%
6M Performance:
+8.81%
1Y Performance:
-72.25%
1-Day Range:
$0.2311
$0.2622
1-Week Range:
$0.2218
$0.2622
52-Week Range:
$0.143
$1.12
Mangoceuticals Inc Stock (MGRX) Company Profile
Name
Mangoceuticals Inc
Sector
Industry
Phone
(833) 626-4679
Address
15110 DALLAS PKWY, SUITE 600, DALLAS
Mangoceuticals Inc Stock (MGRX) Latest News
Mangoceuticals (NASDAQ:MGRX) Trading Down 3.3% - Defense World
Erectile Dysfunction Treatment Market Expected to Expand at - openPR
Mangoceuticals Inc’s latest rating changes from various analysts - Knox Daily
A year in review: Mangoceuticals Inc (MGRX)’s performance in the last year - US Post News
Balance Sheet Breakdown: Mangoceuticals Inc (MGRX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Mangoceuticals Inc (MGRX) Stock: A Year of Declines and Increases - The InvestChronicle
Mangoceuticals Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Market Momentum: Mangoceuticals Inc (MGRX) Registers a -15.70 Decrease, Closing at 0.22 - The Dwinnex
Mangoceuticals issues equity, CEO gets raised car allowance - Investing.com
Mangoceuticals issues equity, CEO gets raised car allowance By Investing.com - Investing.com South Africa
Mangoceuticals Raises Capital and Boosts CEO Perks - TipRanks
Mangoceuticals Second Quarter 2024 Earnings: US$0.092 loss per share (vs US$0.14 loss in 2Q 2023) - Yahoo Finance
Mangoceuticals (NASDAQ:MGRX) Stock Price Down 2.7% - Defense World
MangoRx Reports 1,685% Increase in Shareholders’ Equity - GlobeNewswire
MangoRx Reports 1,685% Increase in Shareholders’ Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024 - StockTitan
Mangoceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
MangoRx secures patent for preventive care tech in India - Investing.com India
MangoRx secures patent for preventive care tech in India By Investing.com - Investing.com Australia
Mangoceuticals Inc (MGRX)’s highs and lows: A closer look at its stock price fluctuations - US Post News
MangoRx secures patent for preventive care tech in India - Investing.com
MangoRx secures patent for preventive care tech in India By Investing.com - Investing.com Canada
MangoRx Receives Certificate of Grant in India for its Respiratory Illness and Preventive Care Technology Patent - GlobeNewswire
MangoRx secures patent for preventive care tech in India By Investing.com - Investing.com UK
MangoRx Receives Certificate of Grant in India for its Respiratory Illness and Preventive Care Technology Patent - StockTitan
Analysts review Mangoceuticals Inc’s rating - Knox Daily
MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide - Marketscreener.com
Stock Performance Spotlight: Mangoceuticals Inc (MGRX) Ends the Day at 0.32, Down by -13.96 - The Dwinnex
Take off with Mangoceuticals Inc (MGRX): Get ready for trading - SETE News
The Psychology of Mangoceuticals Inc Inc. (MGRX) Price Performance: Understanding Market Sentiment - The InvestChronicle
MangoRx Completes Migration to DEA-Approved Telemedicine - GlobeNewswire
Mangoceuticals, Inc. Announces Successful Migration to Its Newly Developed DEA -Approved Telemedicine Operating System - Marketscreener.com
MangoRx Receives Request for Proposal (RFP) From ISFLST for New Male Enhancement Product Exclusive for the Asian Market - AccessWire
MangoRx Receives Request for Proposal (RFP) From ISFLST for New Male Enhancement Product Exclusive for the Asian Market - StockTitan
What was Mangoceuticals Inc (MGRX)’s performance in the last session? - US Post News
Emerging Telemedicine Leaders: Stocks Shaping Healthcare's Digital Future - Marketscreener.com
MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology - GlobeNewswire
MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology - Yahoo Finance
MGRX’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology - StockTitan
Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access - Markets Insider
MangoRx Introduces Revolutionary Oral Testosterone Replacement Therapy - Vancity Buzz
Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access - GlobeNewswire
Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access - Nasdaq
Say Goodbye To Inconvenient TRT: Meet The Game-Changing Oral Testosterone TreatmentPRIME By MangoRx - Nasdaq
Gaining Ground: Mangoceuticals Inc (MGRX) Closes Lower at 0.42, Down -1.37 - The Dwinnex
Ready to Jump After Recent Trade: Mangoceuticals Inc (MGRX) - SETE News
Mangoceuticals Inc (MGRX) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
MangoRx secures DEA nod for telemedicine system - Investing.com
Mangoceuticals Wins DEA Nod - Baystreet.ca
MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts - Marketscreener.com
MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts - GlobeNewswire
Mangoceuticals Inc Stock (MGRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.31%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):